Renal cell carcinoma
References
Key articles
American Urological Association. Renal mass and localized renal cancer: evaluation, management, and follow up. 2021 [internet publication].Full text
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20.Full text Abstract
European Association of Urology. Renal cell carcinoma. 2023 [internet publication].Full text
American College of Radiology. ACR appropriateness criteria: post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. 2021 [internet publication].Full text
Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022 Sep 1;40(25):2957-95.Full text Abstract
Reference articles
1. American Urological Association. Renal mass and localized renal cancer: evaluation, management, and follow up. 2021 [internet publication].Full text
2. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20.Full text Abstract
3. Mattar K, Jewett MA. Watchful waiting for small renal masses. Curr Urol Rep. 2008 Jan;9(1):22-5. Abstract
4. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008 Nov;35(4):627-34; vii. Abstract
5. Richard PO, Violette PD, Bhindi B, et al. Canadian Urological Association guideline: management of small renal masses - full-text. Can Urol Assoc J. 2022 Feb;16(2):E61-75.Full text Abstract
6. Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017 Feb 20;35(6):668-80.Full text Abstract
7. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.
8. Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control. TNM classification of malignant tumors. 8th ed. Chichester: Wiley-Blackwell; 2017.
9. Classification of Tumours Editorial Board. Urinary and male genital tumours. In: WHO classification of tumours, 5th Edition, Volume 8. Lyon, France: IARD Press; 2022.
10. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022 Nov;82(5):458-68.Full text Abstract
11. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013 Oct;37(10):1490-504. Abstract
12. Delahunt B, Eble JN, Egevad L, et al. Grading of renal cell carcinoma. Histopathology. 2019 Jan;74(1):4-17. Abstract
13. Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. 2004 May;231(2):365-71. Abstract
14. Sevcenco S, Spick C, Helbich TH, et al. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. Eur Radiol. 2017 Jun;27(6):2239-47.Full text Abstract
15. Agnello F, Albano D, Micci G, et al. CT and MR imaging of cystic renal lesions. Insights Imaging. 2020 Jan 3;11(1):5.Full text Abstract
16. Kawaciuk I, Hyrsl L, Dusek P, et al. Influence of tumour-associated symptoms on the prognosis of patients with renal cell carcinoma. Scand J Urol Nephrol. 2008;42(5):406-11. Abstract
17. European Association of Urology. Renal cell carcinoma. 2023 [internet publication].Full text
18. Sacco E, Pinto F, Sasso F, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83(1):1-11.Full text Abstract
19. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: kidney and renal pelvis cancer. 2024 [internet publication].Full text
20. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48.Full text Abstract
21. Schafer EJ, Jemal A, Wiese D, et al. Disparities and trends in genitourinary cancer incidence and mortality in the USA. Eur Urol. 2023 Jul;84(1):117-26.Full text Abstract
22. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.Full text Abstract
23. Saad AM, Gad MM, Al-Husseini MJ, et al. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: A SEER-based study. Clin Genitourin Cancer. 2019 Feb;17(1):46-57.e5.Full text Abstract
24. Levi F, Ferlay J, Galeone C, et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 2008 Apr;101(8):949-58.Full text Abstract
25. Haifler M, Neheman A, Zisman A. Has stage migration in renal cancer run its course? A SEER database analysis. Clin Genitourin Cancer. 2020 Aug;18(4):e368-73. Abstract
26. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 Dec;176(6 Pt 1):2353-8. Abstract
27. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019 Jan;75(1):74-84. Abstract
28. Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015 Mar;67(3):519-30.Full text Abstract
29. Sung WW, Wang SC, Hsieh TY, et al. Favorable mortality-to-incidence ratios of kidney cancer are associated with advanced health care systems. BMC Cancer. 2018 Aug 6;18(1):792.Full text Abstract
30. Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016 Mar 7;9:45-52.Full text Abstract
31. Kompotiatis P, Thongprayoon C, Manohar S, et al. Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology (Carlton). 2019 Jan;24(1):65-73. Abstract
32. Chewcharat A, Thongprayoon C, Bathini T, et al. Incidence and mortality of renal cell carcinoma after kidney transplantation: a meta-analysis. J Clin Med. 2019 Apr;8(4):530.Full text Abstract
33. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018 Dec;36(12):1891-8.Full text Abstract
34. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006 Dec 10;24(35):5593-600. Abstract
35. Ashouri K, Mohseni S, Tourtelot J, et al. Implications of von Hippel-Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL. 2015 Sep 25;2(4):163-73.Full text Abstract
36. Aghamir SMK, Heshmat R, Ebrahimi M, et al. The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review. Onco Targets Ther. 2019 Sep 26;12:7929-40.Full text Abstract
37. Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol. 2018 Dec;36(12):1913-26.Full text Abstract
38. Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017 Aug;13(8):496-511. Abstract
39. US Department of Health and Human Services. Smoking cessation: a report of the surgeon general. 2020 [internet publication].Full text
40. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438.Full text Abstract
41. Aurilio G, Piva F, Santoni M, et al. The role of obesity in renal cell carcinoma patients: clinical-pathological implications. Int J Mol Sci. 2019 Nov;20(22):5683.Full text Abstract
42. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013 Nov;190(5):1657-61.Full text Abstract
43. Cumberbatch MG, Rota M, Catto JW, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016 Sep;70(3):458-66.Full text Abstract
44. Petrelli F, Cortellini A, Indini A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open. 2021 Mar 1;4(3):e213520.Full text Abstract
45. Maurits JSF, Sedelaar JPM, Aben KKH, et al. Cohort profile - the Renal cell cancer: lifestyle, prognosis and quality of life (ReLife) study in the Netherlands. BMJ Open. 2023 Mar 27;13(3):e066909.Full text Abstract
46. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008 Feb 15;167(4):438-46.Full text Abstract
47. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008 Sep 3;100(17):1260-2.Full text Abstract
48. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014 Jan;21(1):81-90.Full text Abstract
49. Menko FH, Maher ER. Diagnosis and management of hereditary renal cell cancer. Recent Results Cancer Res. 2016;205:85-104. Abstract
50. Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis. 1995 Jul;26(1):1-12. Abstract
51. Brennan JF, Stilmant MM, Babayan RK, et al. Acquired renal cystic disease: implications for the urologist. Br J Urol. 1991 Apr;67(4):342-8. Abstract
52. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000 Apr;27(2):115-23. Abstract
53. Mandel JS, McLaughlin JK, Schlehofer B, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer. 1995;61:601-5. Abstract
54. Schouten LJ, van de Pol J, Kviatkovsky MJ, et al. Reproductive and external hormonal factors and the risk of renal cell cancer in the Netherlands Cohort Study. Cancer Epidemiol. 2022 Aug;79:102171.Full text Abstract
55. Chiu HF, Kuo CC, Kuo HW, et al. Parity, age at first birth and risk of death from kidney cancer: a population-based cohort study in Taiwan. Eur J Public Health. 2014 Apr;24(2):249-52.Full text Abstract
56. Kabat GC, Silvera SA, Miller AB, et al. A cohort study of reproductive and hormonal factors and renal cell cancer risk in women. Br J Cancer. 2007 Mar 12; 96(5):845–9.Full text Abstract
57. Lee JE, Hankinson SE, Cho E. Reproductive factors and risk of renal cell cancer: the Nurses' Health Study. Am J Epidemiol. 2009;169:1243-50. Abstract
58. Zhang X, Du Y, Tan X, et al. The rRelationship between hormone replacement therapy and risk of kidney cancer in women: a meta-analysis. Cancer Control. 2020 Apr-Jun;27(2):1073274820930194.Full text Abstract
59. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S.Full text Abstract
60. Leveridge MJ, Bostrom PJ, Koulouris G, et al. Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol. 2010 Jun;7(6):311-25. Abstract
61. Meister M, Choyke P, Anderson C, et al. Radiological evaluation, management, and surveillance of renal masses in von Hippel-Lindau disease. Clin Radiol. 2009 Jun;64(6):589-600. Abstract
62. Usher-Smith J, Simmons RK, Rossi SH, et al. Current evidence on screening for renal cancer. Nat Rev Urol. 2020 Nov;17(11):637-42.Full text Abstract
63. National Cancer Comprehensive Network. NCCN clinical practice guidelines in oncology: kidney cancer [internet publication].Full text
64. Lavallée LT, McAlpine K, Kapoor A, et al. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. Can Urol Assoc J. 2019 Dec;13(12):377-83.Full text Abstract
65. Karivedu V, Jain AL, Eluvathingal TJ, et al. Role of positron emission tomography imaging in metabolically active renal cell carcinoma. Curr Urol Rep. 2019 Aug 29;20(10):56. Abstract
66. El-Saeity NS, Sidhu PS. "Scrotal varicocele, exclude a renal tumour": is this evidence based? Clin Radiol. 2006 Jul;61(7):593-9. Abstract
67. Heidenreich A, Ravery V. Preoperative imaging in renal cell cancer. World J Urol. 2004 Nov;22(5):307-15. Abstract
68. Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass. Radiology. 2008 Oct;249(1):16-31. Abstract
69. Dong XQ, Shen Y, Xu LW, et al. Contrast-enhanced ultrasound for detection and diagnosis of renal clear cell carcinoma. Chin Med J (Engl). 2009 May 20;122(10):1179-83. Abstract
70. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU guideline. J Urol. 2020 Oct;204(4):778-86.Full text Abstract
71. Volpe A. The role of active surveillance of small renal masses. Int J Surg. 2016 Dec;36(pt c):518-24.Full text Abstract
72. Sanchez-Ortiz RF, Madsen LT, Bermejo CE, et al. A renal mass in the setting of a nonrenal malignancy: when is a renal tumor biopsy appropriate? Cancer. 2004 Nov 15;101(10):2195-201.Full text Abstract
73. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001 Mar 15;19(6):1649-57. Abstract
74. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN Score. J Urol. 2002 Dec;168(6):2395-400. Abstract
75. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9. Abstract
76. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 Feb;14(2):141-8.Full text Abstract
77. Martini DJ, Liu Y, Shabto JM, et al. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist. 2020 Mar;25(3):e484-91.Full text Abstract
78. Peña C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010 Oct 1;16(19):4853-63. Abstract
79. Calvo E, Porta C, Grünwald V, et al. The current and evolving landscape of first-line treatments for advanced renal cell carcinoma. Oncologist. 2019 Mar;24(3):338-48.Full text Abstract
80. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354.Full text Abstract
81. Roussel E, Campi R, Amparore D, et al. Expanding the role of ultrasound for the characterization of renal masses. J Clin Med. 2022 Feb 19;11(4):1112.Full text Abstract
82. Louise M Binderup M, Smerdel M, Borgwadt L, et al. von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022 Aug;65(8):104538.Full text Abstract
83. Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014 Dec;13(4):637-44.Full text Abstract
84. Quhal F, Mori K, Bruchbacher A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021 Mar 20 [Epub ahead of print].Full text Abstract
85. Pierorazio PM, Johnson MH, Patel HD, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol. 2016 Oct;196(4):989-99.Full text Abstract
86. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009 Jul 1;115(13):2844-52. Abstract
87. American College of Radiology. ACR appropriateness criteria: post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. 2021 [internet publication].Full text
88. Fan X, Xu K, Lin T, et al. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2013 Apr;111(4):611-21. Abstract
89. Masson-Lecomte A, Bensalah K, Seringe E, et al. A prospective comparison of surgical and pathological outcomes obtained after robot-assisted or pure laparoscopic partial nephrectomy in moderate to complex renal tumours: results from a French multicentre collaborative study. BJU Int. 2013 Feb;111(2):256-63. Abstract
90. Xia L, Wang X, Xu T, et al. Systematic review and meta-analysis of comparative studies reporting perioperative outcomes of robot-assisted partial nephrectomy versus open partial nephrectomy. J Endourol. 2017 Sep;31(9):893-909. Abstract
91. Weight CJ, Mulders PF, Pantuck AJ, et al. The role of adrenalectomy in renal cancer. Eur Urol Focus. 2016 Feb;1(3):251-57. Abstract
92. Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012 Jul;188(1):51-7. Abstract
93. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr;59(4):543-52. Abstract
94. Kroon BK, de Bruijn R, Prevoo W, et al. Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology. 2013 Jan;81(1):111-5. Abstract
95. Hatiboglu G, Hohenfellner M, Arslan A, et al. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbecks Arch Surg. 2017 Jun;402(4):637-44. Abstract
96. National Institute for Health and Care Excellence. Pembrolizumab for adjuvant treatment of renal cell carcinoma. Oct 2022 [internet publication].Full text
97. Salagierski M, Wojciechowska A, Zając K, et al. The role of ablation and minimally invasive techniques in the management of small renal masses. Eur Urol Oncol. 2018 Oct;1(5):395-402. Abstract
98. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008 Nov 15;113(10):2671-80.Full text Abstract
99. Haidar GM, Hicks TD, El-Sayed HF, et al. Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):430-36. Abstract
100. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021 Aug 19;385(8):683-94. Abstract
101. Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Sep;23(9):1133-1144.Full text Abstract
102. Choueiri TK, Tomczak P, Park SH, et al. Overall Survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024 Apr 18;390(15):1359-71.Full text Abstract
103. Schrader AJ, Steffens S, Schnoeller TJ, et al. Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? Int J Urol. 2012 Oct;19(10):903-7. Abstract
104. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019 Mar;2(2):141-9. Abstract
105. Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022 Sep 1;40(25):2957-95.Full text Abstract
106. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-27.Full text Abstract
107. Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019 Jan;75(1):111-28. Abstract
108. Kuusk T, Szabados B, Liu WK, et al. Cytoreductive nephrectomy in the current treatment algorithm. Ther Adv Med Oncol. 2019 Sep 27;11:1758835919879026.Full text Abstract
109. Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of surgical management of metastatic renal cell carcinoma. Curr Oncol Rep. 2020 Mar 13;22(4):35. Abstract
110. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-27.Full text Abstract
111. Powles T; ESMO Guidelines Committee. Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Mar;32(3):422-3.Full text Abstract
112. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021 Mar 4;384(9):829-41.Full text Abstract
113. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289-300. Abstract
114. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-85. Abstract
115. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999 Feb;17(2):523-8. Abstract
116. Gulati S, Vaishampayan U. Current state of systemic therapies for advanced renal cell carcinoma. Curr Oncol Rep. 2020 Feb 11;22(3):26. Abstract
117. Motzer RJ, Hutson TE, Reeves J, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. ESMO Congress; October 1, 2012; Vienna. Abstract LBA8.Full text
118. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31.Full text Abstract
119. Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol. 2012;30(suppl):abstract CRA4502).Full text
120. Basso M, Cassano A, Barone C. A survey of therapy for advanced renal cell carcinoma. Urol Oncol. 2010 Mar-Apr;(2):121-33. Abstract
121. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. Abstract
122. George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist. 2019 Nov;24(11):1497-501.Full text Abstract
123. Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-27. Abstract
124. Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 Apr;20(4):581-90.Full text Abstract
125. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473-82. Abstract
126. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. Abstract
127. National Institute for Health and Care Excellence. Everolimus for advanced renal cell carcinoma after previous treatment. February 2017 [internet publication].Full text
128. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.Full text Abstract
129. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103-1115.Full text Abstract
130. Bajwa R, Cheema A, Khan T, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019 Apr;11(4):225-236.Full text Abstract
131. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020 Jan;21(1):95-104. Abstract
132. Pal SK, Escudier BJ, Atkins MB, et al. Final overall survival results from a phase 3 study to compare tivozanib to sorafenib as third- or fourth-line therapy in subjects with metastatic renal cell carcinoma. Eur Urol. 2020 Dec;78(6):783-5. Abstract
133. Calvo E, Maroto P, del Muro XG, et al. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 2010 Aug;29 Suppl 1:11-20. Abstract
134. Hale P, Hahn AW, Rathi N, et al. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. J Geriatr Oncol. 2019 Jan;10(1):149-54. Abstract
135. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1317-24. Abstract
136. Kushnir I, Basappa NS, Ghosh S, et al. Active surveillance in metastatic renal cell carcinoma: results from the Canadian Kidney Cancer Information System. Clin Genitourin Cancer. 2021 Dec;19(6):521-30. Abstract
137. Harrison MR, Costello BA, Bhavsar NA, et al. Active surveillance of metastatic renal cell carcinoma: results from a prospective observational study (MaRCC). Cancer. 2021 Jul 1;127(13):2204-12.Full text Abstract
138. Malouf GG, Joseph RW, Shah AY, et al. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol. 2017 May;15(5):409-18. Abstract
139. Fernández-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017 Mar;71(3):426-36. Abstract
140. Haas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7.Full text Abstract
141. Keskin SK, Msaouel P, Hess KR, et al. Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras. J Urol. 2017 Sep;198(3):530-37.Full text Abstract
142. Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol. 2010 Sep;21(9):1839-45.Full text Abstract
143. Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017 Sep;14(9):549-63. Abstract
144. Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019 Sep;2(5):515-23.Full text Abstract
145. Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015 Feb;54(2):148-57.Full text Abstract
146. He L, Liu Y, Han H, et al. Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Am J Clin Oncol. 2020 Jan;43(1):58-63.Full text Abstract
147. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2008 Apr;34(2):183-92. Abstract
148. National Institute for Health and Care Excellence. Pembrolizumab for adjuvant treatment of renal cell carcinoma. Jan 2023 [internet publication].Full text
149. National Institute for Health and Care Excellence. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma. Mar 2022 [internet publication].Full text
150. ClinicalTrials.gov. A phase 2 study of belzutifan (PT2977, MK-6482) for the treatment of von Hippel Lindau (VHL) disease-associated renal cell carcinoma (RCC) (MK-6482-004). August 2021 [internet publication].Full text
151. Beckermann K, NShah NJ, Vogelzang NJ, et al. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140). J Clin Oncol. Jun 1 2022;40(16);TPS4599-TPS4599.Full text
152. ClinicalTrials.gov. Safety and efficacy study of AVB-S6-500 (batiraxcept) in patients with advanced or metastatic clear cell renal cell carcinoma. NCT04300140. Jan 2023 [internet publication].Full text
153. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Mar;15(3):286-96.Full text Abstract
154. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 Jun 15;393(10189):2404-15. Abstract
155. Fahey CC, Shevach JW, Flippot R, et al. Triplet strategies in metastatic clear cell renal cell carcinoma: a worthy option in the first-line setting? Am Soc Clin Oncol Educ Book. 2023 May;43:e389650.Full text Abstract
156. ClinicalTrials.gov. A study of pembrolizumab (MK-3475) in combination with belzutifan (MK-6482) and lenvatinib (MK-7902), or pembrolizumab/quavonlimab (MK-1308A) in combination with lenvatinib, versus pembrolizumab and lenvatinib, for treatment of advanced clear cell renal cell carcinoma (MK-6482-012). ClinicalTrials.gov Identifier: NCT04736706. Mar 2024 [internet publication].Full text
157. ClinicalTrials.gov. Study of sitravatinib, nivolumab and ipilimumab in advanced or metastatic clear-cell renal cell carcinoma or other solid malignancies. ClinicalTrials.gov Identifier: NCT04518046. Jun 2024 [internet publication].Full text
158. ClinicalTrials.gov. Study of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma (COSMIC-313). ClinicalTrials.gov Identifier: NCT03937219. Aug 2024 [internet publication].Full text
159. Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023 May 11;388(19):1767-78.Full text Abstract
160. Singer EA, Rumble RB, Rathmell WK, et al. Management of metastatic renal clear cell cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Nov 20;41(33):5184-6.Full text Abstract
161. Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 Inhibitor (atezolizumab) in advanced solid tumors. Clin Cancer Res. 2019 Jun 1;25(11):3220-28. Abstract
162. Wegner RE, Abel S, Vemana G, et al. Utilization of stereotactic ablative body radiation therapy for intact renal cell carcinoma: trends in treatment and predictors of outcome. Adv Radiat Oncol. 2020 Jan-Feb;5(1):85-91.Full text Abstract
163. Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018 Mar 1;124(5):934-42. Abstract
164. Correa RJM, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2019 Nov;5(6):958-69.Full text Abstract
165. Ritchie RW, Leslie T, Phillips R, et al. Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up. BJU Int. 2010 Oct;106(7):1004-9.Full text Abstract
166. Ritchie RW, Leslie TA, Turner GD, et al. Laparoscopic high-intensity focused ultrasound for renal tumours: a proof of concept study. BJU Int. 2011 Apr;107(8):1290-6.Full text Abstract
167. Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE. 2011 Apr 20;6(4):e18801.Full text Abstract
168. Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017 Jan;27(1):74-95.Full text Abstract
169. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004 Feb 21;363(9409):594-9. Abstract
170. Koster BD, Santegoets SJAM, Harting J, et al. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. Cancer Immunol Immunother. 2019 Jun;68(6):1025-35.Full text Abstract
171. Donat SM, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013 Aug;190(2):407-16.Full text Abstract
172. Dabestani S, Marconi L, Kuusk T, et al. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018 Dec;36(12):1953-59. Abstract
173. Bazzi WM, Sjoberg DD, Feuerstein MA, et al. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol. 2015 Jun;193(6):1911-6.Full text Abstract
174. Gangadaran SGD. Current management options in metastatic renal cell cancer. Oncol Rev. 2017 Jun 14;11(2):339.Full text Abstract
175. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 2009 Feb 15;115(4):776-83.Full text Abstract
176. Garje R, An J, Greco A, et al. The future of immunotherapy-based combination therapy in metastatic renal cell carcinoma. Cancers (Basel). 2020 Jan 7;12(1):143.Full text Abstract
177. Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005 Jul;48(1):77-81. Abstract
178. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998 Jun;16(6):2261-6. Abstract
179. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002 Apr;73(4):1082-7. Abstract
180. Alasker A, Meskawi M, Sun M, et al. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev. 2013 Jun;39(4):388-401. Abstract
181. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Full text Abstract
182. Williamson TJ, Pearson JR, Ischia J, et al. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016 Apr;117(4):555-62.Full text Abstract
183. Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol. 2007 Jun;51(6):1490-500. Abstract
184. Canadian Kidney Cancer Forum. Management of kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J. 2009 Jun;3(3):200-4.Full text Abstract
185. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008 May;53(5):917-30. Abstract
186. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007 Jan 3;99(1):81-3.Full text Abstract
187. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007 Apr;17(4):351-5. Abstract
188. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009 Apr;6(4):219-28.Full text Abstract
Use of this content is subject to our disclaimer